64 Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms.
Autor: | Carlsen EA; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Johnbeck CB; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Binderup T; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Loft M; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Pfeifer A; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Mortensen J; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Oturai P; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Loft A; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Berthelsen AK; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Langer SW; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark.; Department of Oncology, Rigshospitalet, Copenhagen, Denmark; and., Knigge U; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark.; Departments of Clinical Endocrinology and Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark., Kjaer A; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark akjaer@sund.ku.dk.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2020 Oct; Vol. 61 (10), pp. 1491-1497. Date of Electronic Publication: 2020 Feb 28. |
DOI: | 10.2967/jnumed.119.240143 |
Abstrakt: | Overexpression of somatostatin receptors (SSTRs) in patients with neuroendocrine neoplasms (NENs) is used for both diagnosis and treatment. Receptor density may reflect tumor differentiation and thus be associated with prognosis. Noninvasive visualization and quantification of SSTR density is possible by SSTR imaging (SRI) using PET. Recently, we introduced 64 Cu-DOTATATE for SRI, and we hypothesized that uptake of this tracer could be associated with overall survival (OS) and progression-free survival (PFS). Methods: We evaluated patients with NENs who underwent 64 Cu-DOTATATE PET/CT SRI in 2 prospective studies. Tracer uptake was determined as the maximal SUV (SUV (© 2020 by the Society of Nuclear Medicine and Molecular Imaging.) |
Databáze: | MEDLINE |
Externí odkaz: |